Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Lilly Files Patent Suit against Hospira and Jiangsu Hansoh Pharma

publication date: Jan 31, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eli Lilly & Co. has filed suit against Hospira Inc. (NYSE: HSP), seeking to block the company from selling a generic version of its cancer drug Gemzar. The generic Gemzar is made in China by Jiangsu Hansoh Pharmaceutical Co. Ltd. According to Lilly, the generic drug violates one of its Gemzar patents. More details....

Stock Symbol: (NYSE: LLY)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors